Abstracts tagged "PRO"

Abstract Number: 2373 • 2016 ACR/ARHP Annual Meeting
Patient Preference for Display of Electronic Patient-Reported Outcomes in Osteoarthritis Clinical Trials: Wording Emphasis, Question Format, and Navigation Button Placement
Laura Khurana¹, Ellen Durand¹, Sarah Gary¹, Tony Otero¹, Chris Hall¹, Aisling Ryan², Christopher J. Evans² and Susan Dallabrida¹, ¹ERT, Boston, MA, ²Endpoint Outcomes, Boston, MA
Background/Purpose: Electronic patient-reported outcomes (ePROs) are a reliable method for collecting patient data in osteoarthritis clinical trials and offer many advantages over paper collection; however,…
Abstract Number: 2501 • 2016 ACR/ARHP Annual Meeting
Radiographic Damage in Patients with RA Increases By 8.3% per Year Disease Duration, in the Era of Biologic Dmards. Results from the Scqm Cohort
Ruediger Mueller¹, Katja Heinimann², Rafael Sauter³, Hendrik Schulze-Koops⁴, Tuulikki Sokka-Isler⁵, Michael Schiff⁶ and Johannes von Kempis⁷, ¹Rheumatology, MD, St. Gallen, Switzerland, ²Division of Rheumatology, Immunology and Rehabilitation, Kantonsspital St. Gallen, St. Gallen, Switzerland, ³Clinical Trials Unit, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁴Division for Rheumatology, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany, ⁵Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁶Rheumatology, University of Colorado, Denver, CO, ⁷Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease leading to joint destructions, if untreated. Treatment with biologic DMARDs has shown to favourably influence disease…
Abstract Number: 2635 • 2016 ACR/ARHP Annual Meeting
Using Patient Reported Outcomes to Inform a Treat to Target Treatment Approach in RA
Eric M. Ruderman¹, Jennifer Beaumont², Emily Bacalao¹, George J. Greene², Azra Muftic² and David Cella², ¹Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: The Patient Reported Outcomes Measurement Information System (PROMIS) is an NIH initiative to develop patient-reported outcome measures (PROs) for use across chronic conditions. PROMIS…
Abstract Number: 2679 • 2016 ACR/ARHP Annual Meeting
Clinically Meaningful Improvement of Essdai and Esspri in Patients with Primary SjöGren’s Syndrome in Real Life: A 12-Month Longitudinal Study
Chiara Baldini¹, Francesco Ferro², Nicoletta Luciano², Elena Elefante², Alessandra Tripoli² and Marta Mosca³, ¹Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ²Rheumatology Unit, University of Pisa, Pisa, Italy, ³Clinical and Experimental Medicine, University of Pisa, Rheumatology Unit, Pisa, Italy
Background/Purpose: The increasing use of ESSDAI and patient reported outcomes (PROs) in primary Sjögren’s syndrome (pSS) clinical trials has pointed out that the performance of…
Abstract Number: 1478 • 2015 ACR/ARHP Annual Meeting
Comparison of JIA and RA Patients in the National Data Bank for Rheumatic Diseases
Melissa L. Mannion¹, Sofia Pedro^2,3, Timothy Beukelman⁴, Jeffrey R. Curtis⁵ and Kaleb Michaud³, ¹Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ²Clinical and Translational Research Center, Bioepi, Oeiras, Portugal, ³National Data Bank for Rheumatic Diseases, Wichita, KS, ⁴Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: We aimed to compare patient reported outcomes between adults with juvenile idiopathic arthritis (JIA) and adults with rheumatoid arthritis (RA) with similar disease duration…
Abstract Number: 1491 • 2015 ACR/ARHP Annual Meeting
Effects of Drug Induced Toxicity on Patient Reported Outcomes in Early Rheumatoid Arthritis Treated-to-Target Using Conventional Triple DMARD Therapy
Nasir Wabe¹, Michael Sorich², Mihir Wechalekar^2,3, Leslie Cleland³, Leah McWilliams³, Anita Lee^4,5, Llew Spargo⁴, Robert Metcalf³, Cindy Hall⁴, Susanna Proudman^4,5 and Michael D. Wiese⁶, ¹School of Pharmacy and Medical Sciences and Sansom Institute for Health Research, University of South Australia, Adelaide, Australia, ²Flinders University, Adelaide, Australia, ³Royal Adelaide Hospital, Adelaide, Australia, ⁴Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ⁵Discipline of Medicine, University of Adelaide, Adelaide, Australia, ⁶University of South Australia, Adelaide, Australia
Background/Purpose: While the introduction of the treat-to-target (T2T) strategy is associated with lower disease activity scores in rheumatoid arthritis (RA), the potential for increased toxicity…
Abstract Number: 2111 • 2015 ACR/ARHP Annual Meeting
A Study to Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
Alexandra Steinberg¹, Harinder Chera¹, Yun-Jung Choi¹, Robert Martin¹, Charles McWherter¹, Yunbin Zhang², Pol Boudes¹ and on behalf of the Arhalofenate Anti-Flare Therapy Study Group, ¹Cymabay Therapeutics, Newark, CA, ²INC Research, Raleigh, NC
Background/Purpose: Arhalofenate is a novel Urate-Lowering Anti-Flare Therapy (ULAFT) to treat gout. It lowers serum uric acid (sUA) by blocking URAT1, a tubular UA transporter, and…
Abstract Number: 2263 • 2015 ACR/ARHP Annual Meeting
Construct and Convergent Validity of Four Global Measures of at-Work Productivity Loss in Patients with Rheumatic Diseases
Sarah Leggett¹, Diane Lacaille², Carina Mihai³, Mihai Bojinca⁴, Brendan van As⁵, Suzanne M. Verstappen⁶ and EULAR-PRO worker productivity group, ¹Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre,The University of Manchester, Manchester, United Kingdom, ²Arthritis Research Centre, University of British Columbia, Vancouver, BC, Canada, ³Internal Medicine and Rheumatology, Ion Cantacuzino Hospital, Bucharest, Romania, ⁴Carol Davila University of Medicine and Pharmacy, Internal Medicine and Rheumatology, Cantacuzino Hospital, Bucharest, Romania, ⁵Arthritis Research Canada, Richmond, BC, Canada, ⁶Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Several global measures are available to assess at-work productivity loss in rheumatic diseases. Paucity in research exploring the construct validity of such measures contributes…
Abstract Number: 2602 • 2015 ACR/ARHP Annual Meeting
CCP Antibody Negativity Is Associated with Higher Fatigue in Rheumatoid Arthritis
Laura Cappelli¹, Susan J. Bartlett^2,3, Michelle Jones⁴ and Clifton Bingham⁴, ¹Ste 4500, Johns Hopkins University, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, ³Medicine , Divisions of Clinical Epidemiology, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁴Johns Hopkins University, Baltimore, MD
Background/Purpose: Fatigue in rheumatoid arthritis (RA) is common and highly debilitating. Emerging evidence suggests that seronegative RA patients differ from their seropositive peers in…
Abstract Number: 2624 • 2015 ACR/ARHP Annual Meeting
Preliminary Content Validation of the Patient Reported Outcomes Measurement Information System (PROMIS) Short Forms in People Living with Rheumatoid Arthritis
Anna Kristina Gutierrez¹, Michelle Jones², Susan J. Bartlett^1,3,4 and Clifton O. Bingham III², ¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, ⁴Medicine , Divisions of Clinical Epidemiology, Rheumatology, Respirology, McGill University, Montreal, QC, Canada
Background/Purpose: The process of patient reported outcome (PRO) validation requires demonstration that the concept being measured and the patient experience of the corresponding symptom or…
Abstract Number: 2655 • 2015 ACR/ARHP Annual Meeting
Clinically Important Worsening (CIW) of RA Disease Activity Requiring an Increase in Therapy Can be Identified Using a Combined Patient and Physician Report of Flare
VP Bykerk^1,2, Clifton O. Bingham III³, Ernest H. Choy⁴, Daming Lin², Rieke Alten⁵, Robin Christensen⁶, Daniel E. Furst⁷, Francis Guillemin⁸, Sarah Hewlett⁹, Amye L. Leong¹⁰, Lyn March¹¹, Thasia Woodworth¹², Gilles Boire¹³, Carol Hitchon¹⁴, Shahin Jamal¹⁵, Edward C. Keystone¹⁶, Janet E. Pope¹⁷, J Carter Thorne¹⁸, Diane Tin¹⁹, Susan J. Bartlett^20,21,22 and CATCH Investigators and OMERACT Flare Group, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ⁵Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ⁶The Parker instutute, RC, Copenhagen, Denmark, ⁷Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁸University of Lorraine, Nancy, France, ⁹Academic Rheumatology, University of West of England, Bristol, United Kingdom, ¹⁰Spokesperson; Strategic Relations, BONE AND JOINT DECADE, Santa Barbara, CA, ¹¹Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ¹²Medicine, Division of Rheumatology, David Geffen School of Medicine, Los Angeles, CA, ¹³Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ¹⁴Department of Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ¹⁵Vancouver Coastal Health, Vancouver, BC, Canada, ¹⁶Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁷Monsignor Roney Bldg/Rheum, University of Western Ontario, St Joseph Health Care, London, ON, Canada, ¹⁸University of Toronto, Toronto, ON, Canada, ¹⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ²⁰Medicine , Divisions of Clinical Epidemiology, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²²Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: A reference point for clinically important worsening (CIW) of RA disease activity requiring retreatment or escalation is needed for randomized trials of treatment withdrawal.…
Abstract Number: 676 • 2015 ACR/ARHP Annual Meeting
What Proportion of Patients with Psa Fail to Achieve MDA Based on Patient Reported Outcomes? an Analysis from a Prospective, Observational Registry
Proton Rahman¹, J Antonio Avina-Zubieta², Regan Arendse³, William G Bensen⁴, Philip Baer⁵, John Kelsall⁶, Michael Starr⁷, Jacqueline Stewart⁸, Dalton Sholter⁹, Michel Zummer¹⁰, Leo Picard¹¹, Emmanouil Rampakakis¹², Eliofotisti Psaradellis¹³, Karina Maslova¹⁴, Allen J Lehman¹⁴, Francois Nantel^15,16, Cathy Tkaczyk¹⁷ and Brendan Osborne¹⁷, ¹Medicine, Memorial University, St John's, NF, Canada, ²Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada, ³University of Saskatchewan, Saskatoon, ON, Canada, ⁴St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Section on Rheumatology, Ontario Medical Association/Journal of the Canadian Rheumatology Association, Toronto, ON, Canada, ⁶Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁷Rheumatology, McGill University, Montreal, QC, Canada, ⁸Penticton Regional Hospital, Penticton, BC, Canada, ⁹Rheumatology Associates, Edmonton, AB, Canada, ¹⁰Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, ¹¹Rhumatologie Moncton, Moncton, NB, Canada, ¹²JSS Medical Research, St-Laurent, QC, Canada, ¹³JSS Medical Research, Montreal, QC, Canada, ¹⁴Janssen Inc., Toronto, ON, Canada, ¹⁵Schering Plough Canada Inc., Janssen Inc., Kirkland, QC, QC, Canada, ¹⁶19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹⁷Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Recent treat-to-target guidelines in PsA recommend that minimal disease activity (MDA) is achieved as early as possible. Patient reported outcomes (PROs) have been criticized…
Abstract Number: 2707 • 2014 ACR/ARHP Annual Meeting
Systemic Sclerosis Related Calcinosis: Patients Provide What Specialists Want to Learn
Angela Christensen¹, Samara Khalique², Sophia Cenac³, Kim Fligelstone⁴, Anne Mawdsley⁵, Tracy Frech⁶, Jessica K. Gordon⁷, Murray Baron⁸, Evan Busman⁹, Virginia D. Steen¹⁰ and Lesley Ann Saketkoo¹¹, ¹Tulane University School of Medicine, New Orleans, LA, ²Louisiana State University Health Sciences Center, New Orleans, LA, ³Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University Health Science Center, New Orleans, LA, ⁴Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, ⁵Raynaud's & Scleroderma - Care and Support UK, Cheshire, United Kingdom, ⁶Div of Rheumatology, University of Utah, Salt Lake City, UT, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Pavillion A, Rm 216, Jewish General Hospital, Montreal, QC, Canada, ⁹Atlanta Scleroderma Support Group, Atlanta, GA, ¹⁰Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ¹¹Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA
Background/Purpose: Calcinosis is a disabling, rarely discussed manifestation of SSc for which the natural history and management is poorly understood. Last year, the Scleroderma Clinical…
Abstract Number: 2416 • 2014 ACR/ARHP Annual Meeting
Do Patterns of Joint Swelling or Tenderness in Rheumatoid Arthritis Patients Impact Disease Activity Outcomes and Pain? Implications for Clinical Practice
Regan Arendse¹, John Kelsall², J. Antonio Avina-Zubieta³, Philip Baer⁴, Erica Weinberg⁴, Jude Rodrigues⁵, Algis Jovaisas⁶, Isabelle Fortin⁷, Maqbool Sheriff⁸, Majed M. Khraishi⁹, Emmanouil Rampakakis¹⁰, John S. Sampalis¹⁰, Francois Nantel¹¹, Susan Otawa¹² and Allen J Lehman¹², ¹University of Saskatchewan, Saskatoon, SK, Canada, ²The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ³Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Private Practice, Scarborough, ON, Canada, ⁵Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁶194 Main Street, University of Ottawa, Ottawa, ON, Canada, ⁷Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁸Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁹Nexus Clinical Research, Memorial University of Newfoundland, St Johns, NF, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose This analysis aimed to describe the pattern of specific joint involvement (tender and/or swollen) pre- and post-TNFi treatment and the impact of specific joint…
Abstract Number: 1551 • 2014 ACR/ARHP Annual Meeting
Correlation of Individual HAQ Questions with Disease Activity Measures in Psoriatic Arthritis: Implications for Instrument Reduction
Denis Choquette¹, Carter Thorne², Majed Khraishi³, Isabelle Fortin⁴, Regan Arendse⁵, Andrew Chow⁶, John Kelsall⁷, Milton Baker⁸, Julie Vaillancourt⁹, John S. Sampalis⁹, Francois Nantel¹⁰, Allen J Lehman¹¹, Susan Otawa¹¹ and May Shawi¹⁰, ¹Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Nexus Clinical Research, St John's, NF, Canada, ⁴Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁵University of Saskatchewan, Saskatoon, SK, Canada, ⁶University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁷The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁸University of Victoria, Victoria, BC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose The Health Assessment Questionnaire (HAQ) is commonly used for assessing patient-reported functional status and disease activity in psoriatic arthritis (PsA). However, it has been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].